Revolution Medicines, Inc.
NASDAQRevolution Medicines reports Q1 2026 results today having become one of the most striking momentum stories in biotech this year. The stock closed at $151.07, up 52% over the past month and 7.5% on the week alone — a run that has compressed short interest and left the Street scrambling to lift price targets. The sheer velocity of that rally has already done some of the shorts' work…
Snapshot as of 7 May 2026
Revolution Medicines reports Q1 2026 results today having become one of the most striking momentum stories in biotech this year. The stock closed at $151.07, up 52% over the past month and 7.5% on the week alone — a…
Revolution Medicines heads into its Q1 2026 earnings release with a rare alignment: a landmark clinical publication, a collapsing short position, and a Wall Street analyst community that has spent two weeks racing to…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RVMD — free to start on ORTEX.
Sign up for free →Open RVMD on ORTEX